Innovation in Action: Tackling the Evolving Landscape of Infectious Diseases

October 31, 2025

Pfizer Highlights Advancements in Infectious Disease Research at IDWeek 2025

Infectious diseases continue to pose some of the largest and most complex public health challenges worldwide. As these challenges evolve, Pfizer remains at the forefront of vaccine and therapeutic development in respiratory and infectious diseases, with a robust portfolio that spans bacterial, viral, and fungal infections.

At IDWeek 2025 in Atlanta, Georgia, Pfizer’s diverse infectious disease portfolio was highlighted by data in 46 research abstracts from company- and collaborator-led studies. These findings – along with broader progress across our infectious disease portfolio – reflect the depth and innovation of our R&D pipeline.

Key Highlights from Pfizer’s Infectious Disease Portfolio

COVID-19

Over the past five years, Pfizer and BioNTech's COVID-19 vaccine efforts reflect a continued commitment to addressing this public health challenge, and Pfizer remains focused on understanding the ongoing impact of the disease.
In a late-breaking presentation at IDWeek, Pfizer shared new global survey findings on the ongoing impact of Long COVID on medically vulnerable populations – highlighting the need for greater awareness and stronger community support systems for these at-risk groups.

Lyme Disease

While Lyme disease is considered the most common vector-borne illness in the Northern Hemisphere¹, there are currently no approved human vaccines to protect against the disease.
Pfizer’s Lyme disease vaccine candidate, which is currently in Phase 3 clinical trials in collaboration with Valneva, is the most advanced Lyme disease vaccine candidate currently in clinical development. If successful in clinical trials and approved, it may become the only vaccine available to help protect against Lyme disease.
At IDWeek, Lyme disease presentations reflected Pfizer's comprehensive effort to advance understanding and management of the disease.

Pneumococcal Disease

Pneumococcal disease, caused by bacteria transmitted through airborne droplets or direct contact, can lead to serious infections. These bacteria have over 100 known serotypes, or variations – driving the need for next-generation vaccines that offer broader disease coverage.
Our research shared at IDWeek underscores our commitment to advancing our pneumococcal vaccine portfolio and driving a wider, integrated approach to disease prevention and management.

Clostridioides difficile (C. diff)

C. difficile infection is an urgent public health threat, estimated to cause nearly half a million infections each year in the U.S.², with no vaccine currently available.
Pfizer is currently advancing an updated formulation of our C. diff vaccine candidate, which has the potential to help prevent primary C. diff infection and address a high unmet need.

These advancements underscore Pfizer’s commitment to addressing emerging health threats and driving progress against the infectious diseases that present substantial burdens to global health.

¹Environmental Protection Agency. Climate Change Indicators: Lyme Disease. Updated April 2021. https://www.epa.gov/climate-indicators/climate-change-indicators-lyme-disease

²U.S. Centers for Disease Control and Prevention: “About C. diff.”
https://www.cdc.gov/c-diff/about/?CDC_AAref_Val=https://www.cdc.gov/cdiff/risk.html

Forward-looking statements included herein and in the linked content, including those related to our anticipated operating and financial performance, our research and development strategy and productivity, our product and pipeline advancements and candidates, and our capital allocation strategy and dividend, are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.